Prognostic evaluation in multiple myeloma: An analysis of the impact of new prognostic factors

British Journal of Haematology

Volumn 106, Issue 4, 1999, Pages 1005-1012

  Turesson, I ^a   Abildgaard, N ^b   Ahlgren, T ^a   Dahl, I M ^c   Holmberg, E ^d   Hjorth, M ^e   Nielsen, J L ^b   Oden A ⁱ   Seidel, C ^f   Waage, A ^g   Westin, J ^a   Wisloff F ^h  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e Lidkoping Hospital   (Sweden)

^f NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^g TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^h ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

ⁱ Ullevål University Hospital ^*

Author keywords

Multiple myeloma; Prognostic factors; Risk score; Survival

Indexed keywords

BETA 2 MICROGLOBULIN; CALCIUM ION; INTERLEUKIN 6 RECEPTOR;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; SCORING SYSTEM; SURVIVAL TIME;

EID: 0032824758     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01651.x     Document Type: Article

References (36)

1. Abildgaard, N., Bentzen, S.M., Nielsen, J.L. & Heickendorff, L., for the Nordic Myeloma Study Group (1997) Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxyterminal telopeptide of type I collagen (ICTP). British Journal of Haematology, 96, 103-110.
2. Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, JJ., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New England Journal of Medicine, 335, 91-97.
3. Barlogie, B., Alexanian, R., Dixon, D., Smith, L., Smallwood, L. & Delasalle, K. (1985) Prognostic implication of tumor cell DNA and RNA content in multiple myeloma. Blood, 6, 338-341.
4. Bataille, R., Boccadoro, M., Klein, B., Durie, B. & Pileri, A, (1992) C-reactive protein and β-2-microglobulin produce a simple and powerful myeloma staging system. Blood, 80, 733-737.
5. Bataille, R., Jourdan, M., Zhang, X.G. & Klein, B. (1989) Serum level of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. Journal of Clinical Investigation, 84, 2008-2111.
6. Björkstrand, B., Ljungman, P., Bird, J.M., Samson, D., Brandt, L., Alegre, A., Auzanneau, G., Blade, J., Brunet, S., Carlson, K., Cavo, M., Ferrant, A., Gravett, P., Dc Laurenzi, A., Prentice, H.G., Proctor, S., Remes, K., Troussard, X., Verdonck, L.F., Williams, C. & Gahrton, G. (1995) Autologous stem cell transplantation in multiple myeloma. Results of the European Group for Bone Marrow Transplantation. Stem Cells (Daytona), 13, (Suppl. 12), 140-146.
7. Bladé, J., Rozman, C, Cervantes, K, Reverter, J.C. & Montserrat, M. (1989) A new prognostic system for multiple myeloma based on easily available parameters. British Journal of Haematology, 72, 507-511.
8. Boccadoro, M. & Pileri, A. (1997) Diagnosis, prognosis and standard treatment of multiple myeloma. Hematology/Oncology Clinics of North America, 11, 111-131.
9. Borset, M., Hjorth Hansen, H., Seidel, C., Sundan, A. & Waage, A. (1996) Hepatocyte growth factor and its receptor in multiple myeloma. Blood, 88, 3998-4004.
10. Brandt, R., Hedlöf, E., Åsman, I., Bucht, A. & Tengblad, A. (1987) A convenient radiometric assay for hyaluronan. Acta Otolaryngologica Supplementum, 442, 31-35.
11. Breslow, N.E. & Day, N.E. (1987) Statistical Methods in Cancer Research Volume II, IARC Scientific Publications, Lyon, No. 32, pp. 131-135.
12. Cook, G., Dumbar, M. & Franklin, I.M. (1997) The role of adhesion molecules in multiple myeloma. Acta Haematologica, 97, 81-89.
13. Dahl, I.M., Turesson, I., Holmberg, E, & Lilja, K., for the Nordic Myeloma Study Group (1999) Serum hyaluronan in patients with multiple myeloma: correlation to survival and immunoglobulin concentrations. Blood, 93, 4144-4148.
14. Durie, B. & Salmon, S. (1975) A clinical stagins system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer, 36, 842-854.
15. Fuller, K., Owens, J. & Chambers, T.J. (1995) The effect of hepatocyte growth factor on the behaviour of osteoclasts. Riochemical and Biophysical Research Communications, 212, 334-340.
16. Gregory, W.M., Richards, M.A. & Malpas, J.S. (1992) Combination therapy versus melphalan and prednisone in the treatment of multiple myeloma: an overview of published trials. Journal of Clinical Oncology, 10, 333-342.
17. Greipp, P.R., Lust, J.A., O'Fallon, M., Katzmann, J.A., Witzig, T.E. & Kyle, R.A. (1993) Plasma cell labelling index and †-2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood, 81, 3382-3387.
18. Harousseau, J.L., Attal, M., Divine, M., Marit, G., Leblond, V., Stoppa, A.M., Bourhis, J.H. Caillot, D., Boasson, M., Abgrall, J.E. Facon, T., Linassier, C., Cahn, J-Y., Lamy, T., Troussard, X., Gratecos, N., Pignon, B., Auzanneau, G. & Bataille, R. (1995) Autologous stem cell transplantation after first remission treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma. Blood, 8, 3077-3085.
19. Hjorth, M., and for The Nordic Myeloma Study Group (1996) Interferon-alfa-2b added to melphalan -prednisone for initial and maintenance therapy in multiple myeloma: a randomized controlled trial. Annals of Internal Medicine, 124, 212-222.
20. Jagannath, S., Tricot, G. & Barlogie, B. (1997) Autotransplants in multiple myeloma: pushing the envelope. Hematology/Oncology Clinics of North America, 11, 363-381.
21. Klein, B., Zhang, K., Lu, Z.Y. & Bataille, R. (1995) Interleukin-6 in human multiple myeloma. Blood, 85, 863-872.
22. Kyle, R.A. (1978) Long-term survival in multiple myeloma. New England Journal of Medicine, 19, 314-318.
23. Kyle, R.A. & Bayrd, E.D. (1976) Multiple myeloma: course and prognosis. In: The Monoclonal Gammopathies, New York.
24. Ludwig, H, Nachbaur, D.M., Fritz, E., Krainer, M. & Huber, H. (1991) interleukin-6 is a prognostic factor in multiple myeloma. (Letter). Blood, 77, 2794-2795.
25. Medical Research Council's Working Party on Leukaemia in Adults (1980) Prognostic features in the third MRC myelomatosis trial. British Journal of Cancer, 42, 831-840.
26. Merlini, G.P., Waldenström, J.G. & Jayakar, S.D. (1980) A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood, 55, 1011-1019.
27. Myeloma Trialist's Collaborative Group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overviw of 6633 patients from 27 randomised trials. Journal of Clinical Oncology, 16, 3832-3842.
28. Pelliniemi, T.T., Irjala, K., Mattila, K., Pulkki, K., Rajamäki, A., Tienbaara, A., Laakso, M. & Luhtinen, R. (1995) Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiply myeloma. Finnish Leukemia Group. Blood, 85, 765-771.
29. Pulkki, K., Pelliniemi, T.T., Rajamäki, A., Tienhaara, A., Laakso, M. & Lahtinen, R. (1996) Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. British Journal of Haematology, 92, 370-374.
30. Risteli, J., Elomaa, I., Niemi, S., Novamo, A. & Risteli, I., (1993) Radio-immunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clinical Chemistry, 39, 635-640.
31. Seidel, C., Borset, M., Turesson, I., Abildgaard, N., Sundan, A. & Waage, A. (1998) Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. Blood, 91, 806-812.
32. Stasi, R., Brunetti, M., Parma, A., Di Giulio, C., Terzoli, E. & Pagano, A. (1998) The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Cancer, 82, 1860-1866.
33. Tricot, G., Barlogie, B., Jagannath, S., Bracy, D., Mattox, S., Vesole, D.H., Naucke, S. & Sawyer, J.R. (1995) Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood, 86, 4250-4256.
34. Wislöff, F., Eika, S., Hippe, E., Hjorth, M., Holmberg, E., Kaasa, S., Palva, I. & Westin, J. (1996) Measurement of health-related quality of life in multiple myeloma. British Journal of Haematology, 92, 604-613.
35. Wislöff, F. & Hjorth, M. (1997) Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. British Journal of Haematology, 97, 29-37.
36. Witzig, T.E., Gertz, M.A., Lust, J.A., Kyle, R.A., O'Fallon, W.M. & Greipp, R. (1996) Peripheral blood monoclonal plasma cells as predictor of survival in patients with multiple myeloma. Blood, 88, 1780-1787.